Deal or Case news
NautaDutillh assisted Forbion in a $62.5M Series A financing round by Prilenia Therapeutics B.V. (Prilenia), a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders.

The funding was raised to support two late-stage trials of pridopidine in Huntington Disease (HD) and Amyotrophic Lateral Sclerosis (ALS).

The Series A financing round was led by Forbion and included new investors, Morningside Venture Investments and Sectoral Asset Management. Existing investors Talisman Capital Partners and Genworks 2 also participated in the round. The Series A financing brings the total capital invested in Prilenia since its foundation in September 2018 to $84.5M. As part of this Series A round, a new Dutch Company, Prilenia Therapeutics B.V. has been formed. The new company will hold Israeli subsidiary company Prilenia Neurotherapeutics Ltd.

The NautaDutilh deal team consisted of Ruud Smits, Jeanine Evertse, Eva van Rooijen (Corporate M&A), Elodie Smits, Wijnand Bossenbroek, Marloes van der Laan (Corporate Notarial). NautaDutilh was assisted by Israeli co-counsel Fischer Behar Chen Well Orion & Co.

For more information read Prilenia's press release.

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.